ProMetic has today announced that it has held a successful pre-IND meeting with the FDA to discuss ProMetic's proposed clinical development program for PBI-4050 in patients with IPF (Idiopathic Pulmonary Fibrosis). ProMetic has been given the go ahead to file an IND (expected to be filed Q1 2016) with a view to initiating a placebo based pivotal clinical trial in the US. This would seem to leapfrog a step in the timeline whereby ProMetic was previously first seeking to expand its current open
01 Oct 2015
A winner in a sector under fire?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A winner in a sector under fire?
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
01 Oct 2015 -
Author:
Derren Nathan -
Pages:
7
ProMetic has today announced that it has held a successful pre-IND meeting with the FDA to discuss ProMetic's proposed clinical development program for PBI-4050 in patients with IPF (Idiopathic Pulmonary Fibrosis). ProMetic has been given the go ahead to file an IND (expected to be filed Q1 2016) with a view to initiating a placebo based pivotal clinical trial in the US. This would seem to leapfrog a step in the timeline whereby ProMetic was previously first seeking to expand its current open